NCT03020992View on ClinicalTrials.gov

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

December 21, 2016

Primary Completion Date

December 4, 2019

Study Completion Date

January 23, 2020

Conditions
Axial Spondyloarthritis (axSpA)Anterior Uveitis (AU)
Interventions
DRUG

Certolizumab Pegol

"* pharmaceutical form: solution for infusion in prefilled syringe~* concentration: 200 mg/mL~* route of administration: subcutaneous"

Trial Locations (23)

Unknown

As0007 101, Brno

As0007 103, Brno

As0007 107, Brno

As0007 108, Ostrava

As0007 109, Pardubice

As0007 102, Prague

As0007 105, Prague

As0007 301, Freiburg im Breisgau

As0007 302, München

As0007 303, Münster

As0007 401, Amsterdam

As0007 506, Bialystok

As0007 510, Lublin

As0007 509, Poznan

As0007 511, Poznan

As0007 502, Torun

As0007 501, Warsaw

As0007 505, Warsaw

As0007 504, Wroclaw

As0007 507, Wroclaw

As0007 508, Wroclaw

As0007 604, Barcelona

As0007 601, Córdoba

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT03020992 - A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU | Biotech Hunter | Biotech Hunter